Skip to main content
Figure 2 | BMC Cancer

Figure 2

From: CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients

Figure 2

Right side: example of a patient with negative PETCT findings (a: coronal view; b: transaxial view) and CA15-3 levels of 45.3 UI/mL; left side: the same patient 6 months later with positive PETCT findings (c: coronal view; d: transaxial view) as well as CA15-3 levels of 116.8 UI/mL. Arrows indicate the metastatic sites.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us